Zydus Lifesciences Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Published 24 May 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹1.1L Cr

India business expected to outperform market by 200-400 basis points, driven by innovative portfolio, strong brands, and therapy focus. US business: Expected single-digit growth next year despite no Revlimid revenue; growth driven by base business volume, new product launches, and specialty portfolio scaling up.

From Zydus Lifesciences Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Price

₹1,120

Market Cap

₹1.1L Cr

P/E Ratio

23.3

How does Zydus Lifesciences Ltd rank in Pharmaceuticals & Biotechnology?

Compare Zydus Lifesciences Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Zydus Lifesciences Ltd — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹7.6K Cr, net profit ₹1.3K Cr.

Full financials →

📊 Revenue & Sales Performance

→India business expected to outperform market by 200-400 basis points, driven by innovative portfolio, strong brands, and therapy focus.
→Specialty business in the US (505(b)(2), rare disease portfolio) is currently small but expected to scale up significantly from FY28 onwards.
→US generic business forecasted to maintain a base around $300-310 million with some erosion due to competition but balanced by new product launches.
→International markets growing strongly at 40%+, driven by broad geographic expansion and robust portfolio launches; growth momentum expected to continue.
→Biosimilars business in India is a meaningful contributor; global scale-up of biologics and biosimilars anticipated by FY29-FY30.
→MedTech and CDMO businesses are building platforms with meaningful contributions expected over 3-4 years.
→Specialty oncology growth accelerated by Assertio acquisition with a platform for high-margin, differentiated products like Rolvedon.
→Overall, strong double-digit growth with expected margin expansion despite competitive and investment-related pressures.

📈 Profitability & Margins

→US business: Expected single-digit growth next year despite no Revlimid revenue; growth driven by base business volume, new product launches, and specialty portfolio scaling up.
→Specialty business: Early stage now, with meaningful scale-up anticipated from FY28 onwards.
→Domestic India business: Confident in 200-400 basis points higher growth than the market, driven by innovative portfolio, key brands, and chronic therapies. No major rep investment planned short term.
→International markets: Sustained strong growth at around 40%, expected to continue due to portfolio expansion and good execution.
→Margins: FY27 expected margins in excess of 24%, slightly lower due to competition and Saro launch expenses.
→Inorganic growth: Bolt-on acquisitions, especially in specialty and 505(b)(2) portfolio, planned to drive growth and profitability.
→Other verticals (MedTech, CDMO): Will take 3-4 years for meaningful profitability impact; steady growth expected in Consumer and Medical Devices businesses.

🏗️ Capital Expenditure Plans

→FY27 capex is planned around ₹1,500 crores, reflecting multiple expansion initiatives.
→Quarterly depreciation is approximately ₹550 crores, influenced by capitalized licensing fees related to Mirabegron, which will cease around September 2027.
→Capital allocation priorities include building new capabilities, especially in Specialty and 505(b)(2) portfolios, with bolt-on acquisitions expected to continue.
→Ongoing investments to scale the Specialty business and international markets are emphasized for sustained growth.
→Digital transformation with advanced analytics, automation, and AI is part of operational efficiency improvements.
→Investment in commercialization of Saroglitazar (Saro) includes an additional $70 million planned for FY27.
→Amplitude Medical Devices business aims to improve profitability and growth over the next few years, with distribution consolidation ongoing.
→Assertio acquisition and other inorganic moves are strategic to accelerate specialty oncology presence and add commercial scale.

💰 Fundraising & Capital Structure

→The company currently has a net debt of around ₹4,500 crore, expected to rise close to ₹7,000 crore after buyback and Assertio acquisition, which corresponds to slightly less than one-time net debt to EBITDA.
→Management is comfortable with the current financial metrics and the debt level.
→They continue to look for bolt-on acquisition opportunities in the Specialty 505(B)(2) franchise but have not indicated plans for immediate new debt or equity fundraising.
→The net debt to EBITDA ratio stood at 0.5 times as of March 31, 2026, indicating disciplined financial management despite inorganic growth.
→No explicit mention of future fundraising through debt or equity was made; the focus is on managing current debt and pursuing acquisitions within comfortable leverage parameters.

📋 Order Book & Pipeline

The transcript does not provide specific details on the current or expected order book or pending orders for Zydus Lifesciences. However, relevant insights include: - The US base business is stable around $300-310 million, with some expected erosion due to competition. - Specialty business is currently small but expected to scale up significantly from FY28. - The US specialty oncology strategy is expanding, including the acquisition of Assertio holdings. - International markets are growing strongly, with over 40% growth observed. - Ongoing inorganic initiatives and bolt-on acquisitions, especially in specialty and 505(b)(2) portfolios, are part of growth strategy. - The company is optimistic about scaling up biosimilars and specialty portfolios over the next 3-4 years. No exact numbers or explicit commentary on order book size or pending orders are mentioned in the call transcript.

Key Metrics

What Zydus Lifesciences Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Torrent Pharma. (Q4 FY26)
Consolidated revenue for Q4 FY26 up 42%, EBITDA up 41%, margins stable at ~32% (Page 2). Key concall takeaways from Torrent Pharma.'s Q4 FY26 earnings call…
Kwality Pharmaceuticals Ltd (Q4 FY26)
FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Key concall takeaways from Kwality Pharmaceuticals Ltd's Q4 FY26 earnings call…
RPG Life Sciences Ltd (Q4 FY26)
Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2%…
Sai Parenterals Ltd (Q4 FY26)
Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets. Key concall takeaways from Sai Parenteral's's Q4 FY26…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Zydus Lifesciences Ltd Q4 FY26 results?

What is Zydus Lifesciences Ltd share price analysis?

Zydus Lifesciences Ltd currently shows a neutral. The stock trades at a P/E of 23.3 with a market cap of ₹113,237 Cr. Investors should review the full earnings analysis for detailed insights.

Is Zydus Lifesciences Ltd planning capital expenditure?

FY27 capex is planned around ₹1,500 crores, reflecting multiple expansion initiatives.

Keep Zydus Lifesciences Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.